Uterine Cancer

Clinical Trials

Below is a list of Uterine Cancer clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Molecular Staging Study of Endometrial Cancer (GOG 0210)
This research study is being done to:

• Collect tissue, urine and blood samples from patients who have endometrial cancer.
• Collect information from patients (for example: age, race, level of education, health history, family health history, and treatments for cancer).

Read more

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
OBJECTIVES: Primary - Compare the recurrence-free survival of patients with stage I-IVA endometrial carcinoma treated with adjuvant chemoradiotherapy comprising cisplatin and tumor volume-directed radiotherapy followed by carboplatin and paclitaxel vs carboplatin and paclitaxel alone.
Read more

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer
OBJECTIVES: Primary - To determine if treatment with paclitaxel and carboplatin does not result in an inferior death rate when compared to paclitaxel and ifosfamide in chemotherapy-naïve patients with newly diagnosed stage I-IV persistent or recurrent uterine or ovarian carcinosarcoma.
Read more

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
OBJECTIVES: Primary - To estimate the hazard of progression or death of each treatment with paclitaxel, carboplatin, and bevacizumab vs paclitaxel, carboplatin, and temsirolimus vs ixabepilone, carboplatin, and bevacizumab relative to that of historical controls in patients with advanced or recurrent endometrial cancer.
Read more

Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor
OBJECTIVES: Primary - To determine the response rate and progression-free survival at 6 months in patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, hepatocellular carcinoma, islet cell cancer, or carcinoid tumor treated with temsirolimus and bevacizumab.
Read more